Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | In stock | $ 30.00 | |
25 mg | In stock | $ 51.00 | |
50 mg | In stock | $ 80.00 | |
100 mg | In stock | $ 122.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 29.00 |
Description | SD-169 (SD 169) is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor. |
Targets&IC50 | p38α MAPK:3.2 nM (IC50), p38β MAPK:122 nM (IC50) |
In vivo | Animals were gavaged with Scios SD-169 (10 or 30 mg/kg) or excipient (PEG300) 1 day before and daily after crush injury to the sciatic nerve.?SD-169 is a proprietary oral inhibitor of p38 MAPK activity.?The rate of axonal regeneration was determined by the functional pinch test and was significantly increased in treated animals 8 days after crush injury (P < 0.05;?30 mg/kg dose).?In SD-169-treated animals with nerve transection, nerve fibers regenerating through a silicone chamber were morphologically more mature than untreated nerves when observed 28 days after transection.?TNF immunofluorescence of distal nerve segments after crush injury suggested that SD-169 reduced SC TNF protein[1]. |
Synonyms | SD 169 |
Molecular Weight | 160.17 |
Formula | C9H8N2O |
CAS No. | 1670-87-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (62.43 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SD-169 1670-87-7 MAPK p38 MAPK HSPs p38α kinases SD169 SD 169 protein inhibit Inhibitor heat diabete mitogen-activated proteins shock inhibitor